US 12,194,032 B2
Method of treating focal segmental glomerulosclerosis
Zhenhua Miao, San Carlos, CA (US); Thomas Schall, San Carlos, CA (US); and Rajinder Singh, San Carlos, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by ChemoCentryx, Inc., San Carlos, CA (US)
Filed on Apr. 8, 2022, as Appl. No. 17/658,494.
Application 17/658,494 is a continuation of application No. 16/946,402, filed on Jun. 19, 2020, granted, now 11,324,736.
Application 16/946,402 is a continuation of application No. 15/821,490, filed on Nov. 22, 2017, granted, now 10,973,809, issued on Apr. 13, 2021.
Claims priority of provisional application 62/425,832, filed on Nov. 23, 2016.
Prior Publication US 2022/0226294 A1, Jul. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/444 (2006.01); A61K 31/137 (2006.01); A61K 31/28 (2006.01); A61K 31/403 (2006.01); A61K 31/4178 (2006.01); A61K 31/4184 (2006.01); A61K 31/426 (2006.01); A61K 31/44 (2006.01); A61K 31/4418 (2006.01); A61K 31/4422 (2006.01); A61K 31/519 (2006.01); A61K 31/7034 (2006.01); A61K 35/545 (2015.01); A61K 39/395 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 31/137 (2013.01); A61K 31/28 (2013.01); A61K 31/403 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/426 (2013.01); A61K 31/44 (2013.01); A61K 31/4418 (2013.01); A61K 31/4422 (2013.01); A61K 31/519 (2013.01); A61K 31/7034 (2013.01); A61K 35/545 (2013.01); A61K 39/3955 (2013.01); A61P 13/12 (2018.01)] 20 Claims
 
1. A method of treating nephritis, wherein the nephritis is adenovirus nephritis, anti-TNF-α Therapy-related glomerulonephritis, fibrillary glomerulonephritis, post-infectious glomerulonephritis, post-streptococcal Glomerulonephritis, Nasr Disease, and rapidly progressive glomerulonephritis in a patient in need thereof, comprising administering to the patient an effective amount of a compound of Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is halogen or C1-6 alkyl;
R2 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, or —CN;
R3 is hydrogen, halogen, or C1-6 alkyl;
R4 is hydrogen, halogen, or C1-6 alkyl;
each R5 is independently C1-6 alkyl, —OH, or —NH2;
n is 0, 1, 2, or 3; and
each of A1, A2, and A3 is —CH— or —N—, where at least one of A1, A2, or A3 is —N—.